Individualized Device Choice for Transcatheter Aortic Valve Implantation



Since its introduction less than 20 years ago, transcatheter aortic valve implantation has achieved momentous milestones moving from first-in-man usage to routine application in everyday clinical practice. One of the reasons for the success of transcatheter aortic valve implantation rests on the ongoing refinements in materials and features of available devices, as well as in the actual diversity among devices. To date, several transcatheter aortic valve implantation devices are available, providing ample opportunity for individualized decision-making, in light of operator’s expertise and preferences. Most likely, no device is better than the others for all technical and clinical dimensions, and some patients may benefit from a specific transcatheter aortic valve implantation device and others from other devices. Awaiting additional comparative effectiveness studies focusing on different transcatheter aortic valve implantation devices, clinicians, interventional cardiologists, and surgeons need to become acquainted with the subtleties of each device, to maximize effectiveness and minimize risk, while remaining conscious of costs and resource use.


Choice Device Strategy Transcatheter aortic valve implantation Transcatheter aortic valve replacement 


Conflicts of Interest

Dr. Corcione has consulted for Abbott Vascular. Dr. A. Giordano has consulted for Abbott Vascular and Medtronic.


  1. 1.
    Cribier A, Eltchaninoff H, Bash A, Borenstein N, Tron C, Bauer F, Derumeaux G, Anselme F, Laborde F, Leon MB. Percutaneous transcatheter implantation of an aortic valve prosthesis for calcific aortic stenosis: first human case description. Circulation. 2002;106:3006–8.CrossRefGoogle Scholar
  2. 2.
    Makkar RR, Fontana GP, Jilaihawi H, Kapadia S, Pichard AD, Douglas PS, Thourani VH, Babaliaros VC, Webb JG, Herrmann HC, Bavaria JE, Kodali S, Brown DL, Bowers B, Dewey TM, Svensson LG, Tuzcu M, Moses JW, Williams MR, Siegel RJ, Akin JJ, Anderson WN, Pocock S, Smith CR, Leon MB, PARTNER Trial Investigators. Transcatheter aortic-valve replacement for inoperable severe aortic stenosis. N Engl J Med. 2012;366:1696–704.CrossRefGoogle Scholar
  3. 3.
    Kodali SK, Williams MR, Smith CR, Svensson LG, Webb JG, Makkar RR, Fontana GP, Dewey TM, Thourani VH, Pichard AD, Fischbein M, Szeto WY, Lim S, Greason KL, Teirstein PS, Malaisrie SC, Douglas PS, Hahn RT, Whisenant B, Zajarias A, Wang D, Akin JJ, Anderson WN, Leon MB, PARTNER Trial Investigators. Two-year outcomes after transcatheter or surgical aortic-valve replacement. N Engl J Med. 2012;366:1686–95.CrossRefGoogle Scholar
  4. 4.
    Leon MB, Smith CR, Mack MJ, Makkar RR, Svensson LG, Kodali SK, Thourani VH, Tuzcu EM, Miller DC, Herrmann HC, Doshi D, Cohen DJ, Pichard AD, Kapadia S, Dewey T, Babaliaros V, Szeto WY, Williams MR, Kereiakes D, Zajarias A, Greason KL, Whisenant BK, Hodson RW, Moses JW, Trento A, Brown DL, Fearon WF, Pibarot P, Hahn RT, Jaber WA, Anderson WN, Alu MC, Webb JG, PARTNER 2 Investigators. Transcatheter or surgical aortic-valve replacement in intermediate-risk patients. N Engl J Med. 2016;374:1609–20.CrossRefGoogle Scholar
  5. 5.
    Adams DH, Popma JJ, Reardon MJ, Yakubov SJ, Coselli JS, Deeb GM, Gleason TG, Buchbinder M, Hermiller J Jr, Kleiman NS, Chetcuti S, Heiser J, Merhi W, Zorn G, Tadros P, Robinson N, Petrossian G, Hughes GC, Harrison JK, Conte J, Maini B, Mumtaz M, Chenoweth S, Oh JK, U.S. CoreValve Clinical Investigators. Transcatheter aortic-valve replacement with a self-expanding prosthesis. N Engl J Med. 2014;370:1790–8.CrossRefGoogle Scholar
  6. 6.
    Reardon MJ, Van Mieghem NM, Popma JJ, Kleiman NS, Søndergaard L, Mumtaz M, Adams DH, Deeb GM, Maini B, Gada H, Chetcuti S, Gleason T, Heiser J, Lange R, Merhi W, Oh JK, Olsen PS, Piazza N, Williams M, Windecker S, Yakubov SJ, Grube E, Makkar R, Lee JS, Conte J, Vang E, Nguyen H, Chang Y, Mugglin AS, Serruys PW, Kappetein AP, SURTAVI Investigators. Surgical or transcatheter aortic-valve replacement in intermediate-risk patients. N Engl J Med. 2017;376:1321–31.CrossRefGoogle Scholar
  7. 7.
    Biondi-Zoccai G, Peruzzi M, Abbate A, Gertz ZM, Benedetto U, Tonelli E, D'Ascenzo F, Giordano A, Agostoni P, Frati G. Network meta-analysis on the comparative effectiveness and safety of transcatheter aortic valve implantation with CoreValve or Sapien devices versus surgical replacement. Heart Lung Vessel. 2014;6:232–43.PubMedPubMedCentralGoogle Scholar
  8. 8.
    Abdel-Wahab M, Mehilli J, Frerker C, Neumann FJ, Kurz T, Tölg R, Zachow D, Guerra E, Massberg S, Schäfer U, El-Mawardy M, Richardt G, CHOICE Investigators. Comparison of balloon-expandable vs self-expandable valves in patients undergoing transcatheter aortic valve replacement: the CHOICE randomized clinical trial. JAMA. 2014;311:1503–14.CrossRefGoogle Scholar
  9. 9.
    Giordano A, Corcione N, Biondi-Zoccai G, Berti S, Petronio AS, Pierli C, Presbitero P, Giudice P, Sardella G, Bartorelli AL, Bonmassari R, Indolfi C, Marchese A, Brscic E, Cremonesi A, Testa L, Brambilla N, Bedogni F. Patterns and trends of transcatheter aortic valve implantation in Italy: insights from RISPEVA. J Cardiovasc Med (Hagerstown). 2017;18:96–102.CrossRefGoogle Scholar
  10. 10.
    Gatto L, Biondi-Zoccai G, Romagnoli E, Frati G, Prati F, Giordano A. New-generation devices for transcatheter aortic valve implantation. Minerva Cardioangiol. 2018;66:747–61. Scholar
  11. 11.
    Kappetein AP, Head SJ, Généreux P, Piazza N, van Mieghem NM, Blackstone EH, Brott TG, Cohen DJ, Cutlip DE, van Es GA, Hahn RT, Kirtane AJ, Krucoff MW, Kodali S, Mack MJ, Mehran R, Rodés-Cabau J, Vranckx P, Webb JG, Windecker S, Serruys PW, Leon MB. Updated standardized endpoint definitions for transcatheter aortic valve implantation: the valve academic research consortium-2 consensus document. Eur Heart J. 2012;33:2403–18.CrossRefGoogle Scholar
  12. 12.
    Arora S, Vavalle JP. Transcatheter aortic valve replacement in intermediate and low risk patients-clinical evidence. Ann Cardiothorac Surg. 2017;6:493–7.CrossRefGoogle Scholar
  13. 13.
    Möllmann H, Diemert P, Grube E, Baldus S, Kempfert J, Abizaid A. Symetis ACURATE TF™ aortic bioprosthesis. EuroIntervention. 2013;9:S107–10.CrossRefGoogle Scholar
  14. 14.
    Möllmann H, Walther T, Siqueira D, Diemert P, Treede H, Grube E, Nickenig G, Baldus S, Rudolph T, Kuratani T, Sawa Y, Kempfert J, Kim WK, Abizaid A. Transfemoral TAVI using the self-expanding ACURATE neo prosthesis: one-year outcomes of the multicentre “CE-approval cohort”. EuroIntervention. 2017;13:e1040–6.CrossRefGoogle Scholar
  15. 15.
    Möllmann H, Hengstenberg C, Hilker M, Kerber S, Schäfer U, Rudolph T, Linke A, Franz N, Kuntze T, Nef H, Kappert U, Walther T, Zembala MO, Toggweiler S, Kim WK. Real-world experience using the ACURATE neo prosthesis: 30-day outcomes of 1,000 patients enrolled in the SAVI TF registry. EuroIntervention. 2018;13:e1764–70.CrossRefGoogle Scholar
  16. 16.
    Kim WK, Möllmann H, Liebetrau C, Renker M, Rolf A, Simon P, Van Linden A, Arsalan M, Doss M, Hamm CW, Walther T. The ACURATE neo transcatheter heart valve: a comprehensive analysis of predictors of procedural outcome. JACC Cardiovasc Interv. 2018;11:1721–9. Scholar
  17. 17.
    Wenaweser P, Stortecky S, Schütz T, Praz F, Gloekler S, Windecker S, Elsässer A. Transcatheter aortic valve implantation with the NVT Allegra transcatheter heart valve system: first-in-human experience with a novel self-expanding transcatheter heart valve. EuroIntervention. 2016;12:71–7.CrossRefGoogle Scholar
  18. 18.
    Piazza N, Martucci G, Lachapelle K, de Varennes B, Bilodeau L, Buithieu J, Mylotte D. First-in-human experience with the Medtronic CoreValve Evolut R. EuroIntervention. 2014;9:1260–3.CrossRefGoogle Scholar
  19. 19.
    Noble S, Stortecky S, Heg D, Tueller D, Jeger R, Toggweiler S, Ferrari E, Nietlispach F, Taramasso M, Maisano F, Grünenfelder J, Jüni P, Huber C, Carrel T, Windecker S, Wenaweser P, Roffi M. Comparison of procedural and clinical outcomes with Evolut R versus Medtronic CoreValve: a Swiss TAVI registry analysis. EuroIntervention. 2017;12:e2170–6.CrossRefGoogle Scholar
  20. 20.
    Forrest JK, Mangi AA, Popma JJ, Khabbaz K, Reardon MJ, Kleiman NS, Yakubov SJ, Watson D, Kodali S, George I, Tadros P, Zorn GL 3rd, Brown J, Kipperman R, Saul S, Qiao H, Oh JK, Williams MR. Early outcomes with the Evolut PRO repositionable self-expanding transcatheter aortic valve with pericardial wrap. JACC Cardiovasc Interv. 2018;11:160–8.CrossRefGoogle Scholar
  21. 21.
    Mahtta D, Elgendy IY, Bavry AA. From CoreValve to Evolut PRO: reviewing the journey of self-expanding transcatheter aortic valves. Cardiol Ther. 2017;6:183–92.CrossRefGoogle Scholar
  22. 22.
    Popma JJ, Reardon MJ, Khabbaz K, Harrison JK, Hughes GC, Kodali S, George I, Deeb GM, Chetcuti S, Kipperman R, Brown J, Qiao H, Slater J, Williams MR. Early clinical outcomes after transcatheter aortic valve replacement using a novel self-expanding bioprosthesis in patients with severe aortic stenosis who are suboptimal for surgery: results of the Evolut R US study. JACC Cardiovasc Interv. 2017;10:268–75.CrossRefGoogle Scholar
  23. 23.
    Kuhn C, Frerker C, Meyer AK, Kurz T, Schäfer U, Deuschl F, Abdel-Wahab M, Schewel D, Elghalban A, Kuck KH, Frey N, Frank D. Transcatheter aortic valve implantation with the 34 mm self-expanding CoreValve Evolut R: initial experience in 101 patients from a multicentre registry. EuroIntervention. 2018;14:e301–5.CrossRefGoogle Scholar
  24. 24.
    Schwerg M, Stangl K, Laule M, Stangl V, Dreger H. Valve in valve implantation of the CoreValve Evolut R in degenerated surgical aortic valves. Cardiol J. 2018;25:301–7.CrossRefGoogle Scholar
  25. 25.
    Gooley R, Lockwood S, Antonis P, Meredith IT. The SADRA lotus valve system: a fully repositionable, retrievable prosthesis. Minerva Cardioangiol. 2013;61:45–52.PubMedGoogle Scholar
  26. 26.
    Meredith IT, Worthley SG, Whitbourn RJ, Antonis P, Montarello JK, Newcomb AE, Lockwood S, Haratani N, Allocco DJ, Dawkins KD. Transfemoral aortic valve replacement with the repositionable lotus valve system in high surgical risk patients: the REPRISE I study. EuroIntervention. 2014;9:1264–70.CrossRefGoogle Scholar
  27. 27.
    Meredith IT, Walters DL, Dumonteil N, Worthley SG, Tchétché D, Manoharan G, Blackman DJ, Rioufol G, Hildick-Smith D, Whitbourn RJ, Lefèvre T, Lange R, Müller R, Redwood S, Allocco DJ, Dawkins KD. Transcatheter aortic valve replacement for severe symptomatic aortic stenosis using a repositionable valve system: 30-day primary endpoint results from the REPRISE II study. J Am Coll Cardiol. 2014;64:1339–48.CrossRefGoogle Scholar
  28. 28.
    Ruparelia N, Latib A, Kawamoto H, Buzzatti N, Giannini F, Figini F, Mangieri A, Regazzoli D, Stella S, Sticchi A, Tanaka A, Ancona M, Agricola E, Monaco F, Spagnolo P, Chieffo A, Montorfano M, Alfieri O, Colombo A. A comparison between first-generation and second-generation transcatheter aortic valve implantation (TAVI) devices: a propensity-matched single-center experience. J Invasive Cardiol. 2016;28:210–6.PubMedGoogle Scholar
  29. 29.
    Grover N. Boston Scientific recalls lotus valve heart devices. Reuters Health News. 2017. Accessed 7 Aug 2018.
  30. 30.
    Manoharan G, Spence MS, Rodés-Cabau J, Webb JG. St Jude medical portico valve. EuroIntervention. 2012;8:Q97–101.CrossRefGoogle Scholar
  31. 31.
    Manoharan G, Linke A, Moellmann H, Redwood S, Frerker C, Kovac J, Walther T. Multicentre clinical study evaluating a novel resheathable annular functioning self-expanding transcatheter aortic valve system: safety and performance results at 30 days with the portico system. EuroIntervention. 2016;12:768–74.CrossRefGoogle Scholar
  32. 32.
    Linke A, Holzhey D, Möllmann H, Manoharan G, Schäfer U, Frerker C, Worthley SG, van Boven AJ, Redwood S, Kovac J, Butter C, Søndergaard L, Lauten A, Schymik G, Walther T. Treatment of aortic stenosis with a self-expanding, resheathable transcatheter valve: one-year results of the international multicenter portico transcatheter aortic valve implantation system study. Circ Cardiovasc Interv. 2018;11:e005206.CrossRefGoogle Scholar
  33. 33.
    Tzikas A, Amrane H, Bedogni F, Brambilla N, Kefer J, Manoharan G, Makkar R, Möllman H, Rodés-Cabau J, Schäfer U, Settergren M, Spargias K, van Boven A, Walther T, Worthley SG, Sondergaard L. Transcatheter aortic valve replacement using the portico system: 10 things to remember. J Interv Cardiol. 2016;29:523–9.CrossRefGoogle Scholar
  34. 34.
    Wendler O, Schymik G, Treede H, Baumgartner H, Dumonteil N, Ihlberg L, Neumann FJ, Tarantini G, Zamarano JL, Vahanian A. SOURCE 3 registry: design and 30-day results of the European Postapproval registry of the latest generation of the SAPIEN 3 transcatheter heart valve. Circulation. 2017;135:1123–32.CrossRefGoogle Scholar
  35. 35.
    Mauri V, Reimann A, Stern D, Scherner M, Kuhn E, Rudolph V, Rosenkranz S, Eghbalzadeh K, Friedrichs K, Wahlers T, Baldus S, Madershahian N, Rudolph TK. Predictors of permanent pacemaker implantation after transcatheter aortic valve replacement with the SAPIEN 3. JACC Cardiovasc Interv. 2016;9:2200–9.CrossRefGoogle Scholar
  36. 36.
    Miyasaka M, Tada N, Taguri M, Kato S, Enta Y, Otomo T, Hata M, Watanabe Y, Naganuma T, Araki M, Yamanaka F, Shirai S, Ueno H, Mizutani K, Tabata M, Higashimori A, Takagi K, Yamamoto M, Hayashida K, OCEAN-TAVI Investigators. Incidence, predictors, and clinical impact of prosthesis-patient mismatch following transcatheter aortic valve replacement in Asian patients: the OCEAN-TAVI |registry. JACC Cardiovasc Interv. 2018;11(8):771–80.CrossRefGoogle Scholar
  37. 37.
    Ohno Y, Tamburino C, Barbanti M. Transcatheter aortic valve implantation experience with SAPIEN 3. Minerva Cardioangiol. 2015;63:205–16.PubMedGoogle Scholar
  38. 38.
    Facchin M, Mojoli M, Covolo E, Tarantini G. The SAPIEN 3 valve: lights and shadows. Minerva Med. 2014;105:497–500.PubMedGoogle Scholar
  39. 39.
    Baumgartner H, Falk V, Bax JJ, De Bonis M, Hamm C, Holm PJ, Iung B, Lancellotti P, Lansac E, Rodriguez Muñoz D, Rosenhek R, Sjögren J, Tornos Mas P, Vahanian A, Walther T, Wendler O, Windecker S, Zamorano JL, ESC Scientific Document Group. 2017 ESC/EACTS guidelines for the management of valvular heart disease. Eur Heart J. 2017;38:2739–91.CrossRefGoogle Scholar
  40. 40.
    Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP 3rd, Fleisher LA, Jneid H, Mack MJ, McLeod CJ, O'Gara PT, Rigolin VH, Sundt TM 3rd, Thompson A. 2017 AHA/ACC focused update of the 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines. J Am Coll Cardiol. 2017;70:252–89.CrossRefGoogle Scholar
  41. 41.
    Abawi M, Agostoni P, Kooistra NHM, Samim M, Nijhoff F, Voskuil M, Nathoe H, Doevendans PA, Chamuleau SA, Urgel K, Hendrikse J, Leiner T, Abrahams AC, van der Worp B, Stella PR. Rationale and design of the Edwards SAPIEN-3 periprosthetic leakage evaluation versus Medtronic CoreValve in transfemoral aortic valve implantation (ELECT) trial: a randomised comparison of balloon-expandable versus self-expanding transcatheter aortic valve prostheses. Neth Hear J. 2017;25:318–29.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Interventional Cardiology UnitPineta Grande HospitalCastel VolturnoItaly
  2. 2.Unità Operativa di EmodinamicaCasa di Salute Santa LuciaSan Giuseppe VesuvianoItaly

Personalised recommendations